London, Jan 28, 2026, 09:00 GMT — Regular session
GSK shares fell 1.8% to 1,828.5 pence by mid-morning Wednesday in London, retreating after two days higher. The stock slipped 34 pence from Tuesday’s close, with about 951,000 shares traded, per LSE data. London South East
GSK’s shares fell following Monday’s news that the European Commission broadened its approval of the RSV vaccine Arexvy to include all adults aged 18 and older. Previously, the vaccine was authorized in the EU only for older adults and select high-risk groups. The company stressed RSV’s danger to adults, noting its potential to cause lower airway and lung infections. “This approval helps protect all adults aged 18 and older in Europe against RSV,” said Sanjay Gurunathan, head of vaccines R&D, in the filing. SEC
This matters because the vaccinated population’s size hinges on national guidelines and funding, not just a labeling update. Investors want to see if European health agencies and governments move quickly to turn wider approval into clear guidance, purchase commitments, and reimbursement strategies ahead of this winter’s RSV season.
The FTSE 100 crept higher by about 0.1% in early trading. Reuters
GSK climbed 1.9% on Tuesday, finishing at 18.63 pounds, outperforming the FTSE 100, which rose 0.6%, according to MarketWatch data. MarketWatch
The battle for RSV shots is intensifying. Pfizer revealed the European Commission has expanded approval for its RSV vaccine Abrysvo to include adults aged 18 to 59. This extension offers policymakers across Europe a fresh option. Pfizer
That said, a broader label doesn’t guarantee steady sales growth. Vaccination rules differ by country, budgets can stall, and demand often hinges on how severe the season ends up being.
GSK will update investors on February 4, unveiling its full-year and Q4 results at 0700 GMT, according to the company’s schedule. GSK
This week, all eyes will be on any updates from EU advisory groups and top health ministries regarding RSV vaccines for working-age adults. Investors will also scrutinize GSK’s report next Wednesday for clues about short-term demand shifts.
